News

Flu vaccines highly effective for pregnant women and their children


 

FROM JOURNAL OF VACCINES & VACCINATION

References

Administering flu vaccines to pregnant women during their second and third trimesters results in high seroprotection against all influenza strains for most women and for more than half of their newly born babies, reported Dr. M.P. Kostinov and colleagues at the I.I. Mechnikov Scientific Research Institute of Vaccines and Sera, at Ul’yanovsk State University, Moscow. The study was published in the Journal of Vaccines & Vaccination.

Researchers gave influenza vaccines (the Grippol Plus vaccine) to 27 women in their second trimesters and 21 women in their third trimesters of pregnancy during 2010-2012. Each 0.5-mL dose of the preservative-free vaccine contained antigens of the following strains: A/California/7/2009/H1N1/v-like (5 mcg), A/H3N2/(Victoria)-like (5 mcg), and B/Brisbane-like (5 mcg) flu.

kdshutterman/Thinkstock.com

Within 1 month after vaccination, the seroprotection rate against all influenza strains was above the recommended threshold level of 1:40 in more than 70% of pregnant women. A gradual decrease in the seroprotection rates against all three influenza strains was reported in the postpartum period.

In infants, protective levels of antibodies were detected within 2-3 days of delivery and ranged from 52% to 62% regardless of the trimester when the vaccination was given. Within 3 months, this seroprotection decreased, and within 6 months it disappeared. The mothers’ protective levels against vaccine strains were 46%-65% after delivery.

Read the article in the Journal of Vaccines & Vaccination (Pakhomov et al. J Vaccines Vaccin. 2015,6:5).

Recommended Reading

Quadrivalent HPV vaccine treats recalcitrant warts in preadolescent children
MDedge Infectious Disease
Shingles vaccine protection lasted 5-6 years in autoimmune disease patients
MDedge Infectious Disease
Progress toward measles elimination slows
MDedge Infectious Disease
Staphylococcus aureus vaccine tolerable, immunogenic in preliminary study
MDedge Infectious Disease
Improved supply chain, immunization rates key to global vaccination success
MDedge Infectious Disease
Afghanistan still struggling with poliovirus
MDedge Infectious Disease
Shingles vaccine protection lasted about 5 years in autoimmune disease patients
MDedge Infectious Disease
ACR: Don’t give pneumococcal vaccine to CAPS, Behçet’s patients
MDedge Infectious Disease
Prime-boost flu vaccination strategy effective in children
MDedge Infectious Disease
Study: Exposure history critical to design of universal flu vaccine
MDedge Infectious Disease